Drug
CBP-8 gallium GA-68 clinical trials
- studies test it
- 5
- open now
- 5
- in phase 3
- 0
- first study started
- 2018
Keep track of what changes. Save the CBP-8 gallium GA-68 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
5 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 5
Massachusetts General Hospital (3) · Peter Caravan (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses CBP-8 gallium GA-68 is read from its arms, and is right about nine times in ten.
Testing it · 5
- Advanced Imaging to Assess the Effect of Immunosuppression on Progressive FibrosisRecruitingPhase 2Peter CaravanNCT07572383Written as [68Ga]CBP8
- Advanced Imaging for Pulmonary FibrosisRecruitingPhase 2Peter CaravanNCT06532071Written as [68Ga]CBP8
- Collagen-targeted PET Imaging for Early Interstitial Lung DiseaseRecruitingPhase 2Massachusetts General HospitalNCT05417776Written as [68Ga]CBP8
- Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue InjuryRecruitingPhase 2Massachusetts General HospitalNCT04485286Written as [68Ga]CBP8
- Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis PatientsRecruitingPhase 1Massachusetts General HospitalNCT03535545Written as [68Ga]CBP8
Codes
What other systems call CBP-8 gallium GA-68 · ClinicalTrials.gg INT018305
- UNII (FDA) W4K4DZ2XVUCBP-8 GALLIUM GA-68One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W4K4DZ2XVU | CBP-8 GALLIUM GA-68 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.